Quality Investor
MarketsPortfolioAbout 

Amarin Corporation plc

Rank #349Decline

AMRN · Nasdaq · Healthcare

Amarin Corporation plc (AMRN) — Rank #349 by gross profitability (GP/assets 0.19) · ROE -8.7% · Piotroski F-Score N/A.

As-of 2026-09-28 · CIK 0000897448 · all metrics point-in-time as of the filing date.

About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.

Show more

It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.

Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Industry
Drug Manufacturers - General
Sector
Healthcare
State
X0
Filer Category
Accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/E, P/B, and dividend yield matter most — book value provides a floor.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

80

Industry

Drug Manufacturers - General

Exchange

Nasdaq

Signal Flags

1 green1 red
Revenue growth acceleratingGrowth rate increasing year over year
Revenue declining YoYRevenue contracted year over year

Quality Profile

Profitability

1/1 pass
GP / assets
0.19
Return on equity
-8.7%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.41
Current ratio
3.67×
Net cash
$314.65M

Cash Flow

1/1 pass
Positive FCF
N/A
Cash-backed earnings
N/A
Accruals healthy
PASS
SBC / revenue
6.5%

Growth

1/2 pass
Revenue growth
-6.5%
Piotroski F-Score
N/A
Share dilution
1.0%

Terry Smith quality gate

Passes 1/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

Asset value and restructuring potential (balance-sheet strength) are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.19

Primary signal (Novy-Marx).

11th of 12 SIC 2834 peers

Return on equity

-8.7%

Gross margin

56.6%

10th of 12 SIC 2834 peers

Revenue growth (YoY)

-6.5%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

-16.7%

Revenue CAGR (5Y)

-19.0%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

—

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.41

4th of 12 SIC 2834 peers (best = lowest)

Current ratio

3.67×

3rd of 12 SIC 2834 peers

Quick ratio

2.48×

Net cash

$314.65M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

—

Operating cash flow minus capex.

Positive free cash flow

N/A

FCF / net income

—

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

N/A

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

6.5%

Stock-based comp intensity.

Piotroski F-Score

F-Score

N/A

Only 8/9 components determinable.

Lifecycle Phase History

20202025
Hypergrowth
Value
Decline
View full financial statements →